FDA Must Revisit MiMedx Wound Care Powder Classification
By Danielle Ferguson · September 22, 2026, 7:57 PM EDT
A Georgia federal judge vacated the Food and Drug Administration's classification of biomedical company MiMedx's wound care treatment as a biological product, which carries heightened regulatory requirements, finding the agency's determination...
To view the full article, register now.